Bright Minds Biosciences (DRUG) added ~10% in the premarket on Tuesday after the company said that its lead asset, BMB-101, succeeded in a mid-stage trial for adults with Absence Seizures and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results